Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMert Ersan

About this trial

This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.

Eligibility criteria

Qualifiers

• Adults aged 18 to 65 years

Individuals presenting facial skin aging signs

Willingness to undergo three intradermal treatment sessions

Ability to comply with study visits and follow-up assessments

Disqualifiers

Pregnancy or breastfeeding

Active skin infection, inflammatory skin disease, or open wounds in the treatment area

History of allergic reactions to injectable dermatologic treatments

Use of systemic or topical retinoids within the past 6 months

Trial design

Treatments tested in this trial

  • Mesenchymal Stem Cell-Derived Exosome

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Mert Ersan

Lead sponsor

Yeditepe University Hospital

Sponsor institution